Why IMU is a multi multi bagger, page-22235

Hi Shaunbra,
The data that has been embargoed until the commencement of the AACR 2024 annual meeting on April 5th pertains to the full publication of the abstract for the presentation. Typically, the titles of the abstracts are released first, in this case March 5th, and the full contents are embargoed until the conference commences.

It is important to note the timeline involved in conference presentations. When a company submits an application to present, in this case November 19th 2023, can be up to six months before the presentation date.

In the SITC 2023 conference Imugene's presentation was categorized as a trial in progress which precluded the publication of trial results. And the company having seen positive early signals in the trial announced an update to the market two days after. A second update of trial results was announced two days prior to ASCO GI 2024 where Imugene presented a subset of the MAST trial results that pertained to gastrointestinal solid tumors.

The trial results released via announcements to the market do not always align to what is presented at conferences but provide context to what is being presented.